Oculus (OCLS) Gets Chinese SFDA Approval for Microcyn Hydrogel

Article Stock Quotes (1) Comments (0)

Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today announced that the Chinese State Food and Drug Administration (SFDA) has approved Microcyn Hydrogel for moistening, repairing and healing of acute and chronic wounds in China. This approval allows Oculus' Chinese partner, Shanghai Sunvic, to market Microcyn Hydrogel in both the over-the-counter and professional healthcare markets in China. Shanghai Sunvic plans to launch the Microcyn hydrogel in the third quarter of 2012.

This approval follows successful completion of randomized trials at five major Chinese hospitals for use of Microcyn Hydrogel in the treatment of acute wounds, diabetic foot care and post-surgical incisions.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Merck (MRK) Says Efficacy Not Achieved in Preladenant Phase 3s; Will Discontinue
• Brocade (BRCD), A10 Settle Litigation; Brocade to Get $5M Cash, $70M Conv. Note
• Gleacher & Co. (GLCH) Reports Election of Five for Board Members

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?